EDDA

EDDA Technology is proud to announce IQQA®-BodyImaging Provides 3D assessment in ACCLAIM Trial conducted by SIO

Retrieved on: 
Monday, April 18, 2022
CEO, MWA, Board, Technology, WCIO, Research, MR, Hospital, Education, Confirmation, Review, Director, Radiation, Intervention, Society, Ecosystem, CT, Ablation, SIO, 3D, Nominal interest rate, Interventional oncology, Transplant, IO, Physician, EDDA, Association, Medical imaging

IQQA-BodyImaging Interventional will be used to provide 3D assessment of the ablation zone and margin for selected colorectal liver metastases.

Key Points: 
  • IQQA-BodyImaging Interventional will be used to provide 3D assessment of the ablation zone and margin for selected colorectal liver metastases.
  • The ACCLAIM study will estimate disease-free survival of colorectal liver metastases treated with MWA incorporating 3D ablation software (EDDA Technology) margin confirmation intraoperatively and through a subsequent independent review centralized validation process.
  • The IQQAplatform provides comprehensive 3D image analysis using MR and CT, and has been used in over 80,000 cases worldwide for surgery and treatment with substantial time-saving.
  • The Society of Interventional Oncology (SIO) is a non-profit association that supports and promotes the field of interventional oncology (IO).